An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 14 Nov 2017 Planned End Date changed from 1 Apr 2018 to 23 Jun 2018.
- 14 Nov 2017 Planned primary completion date changed from 1 Apr 2018 to 23 Jun 2018.
- 11 Jul 2016 Status changed from not yet recruiting to recruiting.